Literature DB >> 1610408

In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions.

S Ponchaut1, F van Hoof, K Veitch.   

Abstract

The inhibitory effects of valproate (VPA) and nine of its metabolites on mitochondrial oxidations have been investigated. Valproate, 4-ene-VPE, 2,4-diene-VPA and 2-propylglutaric acid inhibited the rate of oxygen consumption by rat liver mitochondrial fractions with long- and medium-chain fatty acids, glutamate (+/- malate), succinate, alpha-ketoglutarate (+ malate) and pyruvate (+ malate) as substrates. Sequestration of intramitochondrial free CoA by valproate and these three metabolites has been demonstrated and quantified. However, CoA trapping could not account for all the inhibitions observed. 2-ene-VPA and 3-oxo-VPA, metabolites formed during the beta-oxidation of valproate, were not capable of trapping intramitochondrial CoA although they were inhibitors of the beta-oxidation of decanoate, probably by inhibition of the medium-chain acyl-CoA synthetase.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1610408     DOI: 10.1016/0006-2952(92)90324-c

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  23 in total

1.  Flux control analysis of mitochondrial oxidative phosphorylation in rat skeletal muscle: pyruvate and palmitoyl-carnitine as substrates give different control patterns.

Authors:  Anette J Fritzen; Niels Grunnet; Bjørn Quistorff
Journal:  Eur J Appl Physiol       Date:  2007-08-24       Impact factor: 3.078

2.  Valproate inhibits the mitochondrial pyruvate-driven oxidative phosphorylation in vitro.

Authors:  M F Silva; J P Ruiter; L Illst; C Jakobs; M Duran; I T de Almeida; R J Wanders
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

3.  In vitro effects of antidepressants and mood-stabilizing drugs on cell energy metabolism.

Authors:  Tereza Cikánková; Zdeněk Fišar; Jana Hroudová
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-19       Impact factor: 3.000

4.  Combined effects of a high-fat diet and chronic valproic acid treatment on hepatic steatosis and hepatotoxicity in rats.

Authors:  Li-fang Zhang; Ling-sheng Liu; Xiao-man Chu; Hao Xie; Li-juan Cao; Cen Guo; Ji-ye A; Bei Cao; Meng-jie Li; Guang-ji Wang; Hai-ping Hao
Journal:  Acta Pharmacol Sin       Date:  2014-01-20       Impact factor: 6.150

Review 5.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

6.  Riboflavin-responsive epilepsy in a patient with SER209 variant form of short-chain acyl-CoA dehydrogenase.

Authors:  S Kmoch; J Zeman; M Hrebícek; L Ryba; M J Kristensen; N Gregersen
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

7.  Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States.

Authors:  Ayse L Mindikoglu; Dale King; Laurence S Magder; John A Ozolek; George V Mazariegos; Benjamin L Shneider
Journal:  J Pediatr       Date:  2010-12-16       Impact factor: 4.406

8.  4-Hydroxy-2(E)-nonenal (HNE) catabolism and formation of HNE adducts are modulated by β oxidation of fatty acids in the isolated rat heart.

Authors:  Qingling Li; Sushabhan Sadhukhan; Jessica M Berthiaume; Rafael A Ibarra; Hui Tang; Shuang Deng; Eric Hamilton; Laura E Nagy; Gregory P Tochtrop; Guo-Fang Zhang
Journal:  Free Radic Biol Med       Date:  2013-01-15       Impact factor: 7.376

Review 9.  Biochemical mechanisms in drug-induced liver injury: certainties and doubts.

Authors:  Ignazio Grattagliano; Leonilde Bonfrate; Catia V Diogo; Helen H Wang; David Q H Wang; Piero Portincasa
Journal:  World J Gastroenterol       Date:  2009-10-21       Impact factor: 5.742

10.  Glucose metabolism as a target of histone deacetylase inhibitors.

Authors:  Suzanne E Wardell; Olga R Ilkayeva; Heather L Wieman; Daniel E Frigo; Jeffrey C Rathmell; Christopher B Newgard; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2008-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.